Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI
PaperCitations, authors & open-access status
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1 citations, 2023 year and bronze oa status.
1
Citations
2023
Year
bronze
OA Status